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supports a gain-of-function mechanism in
C9orf72-associated ALS and FTD
Renate K Hukema1,7*†, Fréderike W Riemslagh1,2†, Shamiram Melhem2, Herma C van der Linde1,
Lies-Anne WFM Severijnen1, Dieter Edbauer3, Alex Maas4, Nicolas Charlet-Berguerand5, Rob Willemsen1†
and John C van Swieten2,6† IET
RA
CT
E
Frontotemporal dementia (FTD) and amyotrophic lateral
sclerosis (ALS) are two neurodegenerative disorders that
share clinical, genetic and pathological overlap. In 2011,
a hexanucleotide repeat (GGGGCC) expansion in the
‘chromosome 9 open reading frame 72’ (C9orf72) gene
was identified as a cause of FTD and ALS [1,2]. This
mutation has proven to be the most common genetic
defect in the neurodegenerative field, especially in FTD
and ALS [3]. Patients harboring the C9orf72 repeat
expansion can develop FTD, ALS or both and are there-
fore associated with wide clinical diversity [4]. There
have been multiple hypotheses about the underlying
mechanisms by which the repeat expansion leads to
neuropathology, including loss-of-function caused by
haploinsufficiency of the endogenous C9orf72 protein
product or gain-of-function induced by either RNA or
protein toxicity. Either free RNA molecules containing
the repeat expansion or RNA foci that sequester proteins
could be toxic for cells. Alternatively, a pathogenic
mechanism has been proposed for the production of toxic
dipeptide repeat proteins (DPR) by repeat-associated non-
AUG translation (RAN) of the repeat [5,6]. Interestingly,
to differentiate between repeat “RNA-only” and DPR pro-
tein toxicity fruit fly models carrying a range of pure and
RNA-only repeats have been generated. These studies
demonstrated that the major toxic species were the DPR
proteins [7].R
* Correspondence: r.hukema@erasmusmc.nl
†Equal contributors
1Department of Clinical Genetics, Erasmus Medical Center, 3015 CE
Rotterdam, The Netherlands
7PO Box 2040, 3000 CA Rotterdam, The Netherlands
Full list of author information is available at the end of the article
© 2014 Hukema et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.D A
RTHere we report on an “RNA-only” gain-of-functionmouse model. To study the intrinsic effect of the repeatwithout assessing its effect on the C9orf72 gene, wecreated a spatially and temporally inducible transgenic
mouse model. This mouse model has a repeat size of
80 GGGGCC-repeats, without human flanking regions,
which may affect repeat translation. This repeat was
cloned in the 5′ UTR of a GFP reporter gene and
controlled by a tetracycline responsive element (TRE)
promoter (Figure 1A). To enable expression of the TRE-
construct we created bigenic mice that possess both the
TRE-construct and the tetracycline-responsive transcrip-
tional activator (rtTA) under a general heterogeneous nu-
clear ribonucleoprotein (hnRNP) promoter [8]. Expression
of the repeat was turned on after weaning by adding doxy-
cycline (dox) to the drinking water. Expression of the re-
peat construct can be stopped at any time by withdrawal
of dox, allowing for reversibility studies (Figure 1A; more
information about the creation of the model can be found
in Additional file 1). After generation of transgenic mice,
the repeat size remained stable for multiple generations
(data not shown). GFP expression was seen in bigenic
mice as soon as 4 days after dox treatment started and
remained stable over time (assessed by western blot of
liver homogenates, data not shown). Next to liver, multiple
other tissues showed GFP expression including lung, kid-
ney and brain; with most prominent expression in the
striatum (Figure 1B) and the cuneate nucleus in the
brainstem.
Both ubiquitin-positive, TDP-43-positive and TDP-43
negative neuronal and cytoplasmic inclusions are patho-
logical hallmarks in post mortem brain tissue froml Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Expression of 80GGGGCC-repeats leads to the formation of ubiquitin-positive inclusions in mouse brain. A) Schematic of the
model used to create the inducible mice. Simultaneous expression of rtTA and doxycycline treatment are needed to drive expression of the
TRE-80GGGGCC-eGFP construct. PCR for determining repeat size in three transgenic mice containing the repeat construct. B) GFP expression in the
striatum of bigenic mice after 12 weeks dox treatment. C) Intranuclear (arrows) and neuropil (arrowheads) ubiquitin-positive inclusionsin the striatum of
bigenic mice after 12 weeks dox treatment.
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TEC9orf72 FTD and ALS patients. We used the presenceof inclusions as a readout for the effect of expression ofthe repeat in our “RNA-only” gain-of-function ALS/FTD
model [9,10]. We found ubiquitin-positive inclusions in
those brain regions that express high levels of GFP, includ-
ing the striatum (Figure 1C) and the cuneate nucleus of
bigenic mice after twelve weeks of dox treatment (n = 7
mice per group). Inclusions were found in the nuclei and
the neuropil in striatum and mainly in the nuclei in the
cuneate nucleus. The presence of ubiquitin-positive inclu-
sions in our mouse model is a shared phenomenon with
non-C9orf72 mouse models of ALS and FTD [11,12]. We
did not observe any TDP-43 positive nor p409/410 TDP-
43 positive inclusions in our mouse model after twelve
weeks of dox treatment, despite the positive staining in a
C9orf72 patient hippocampus control (data not shown).
TDP-43 inclusions might only appear after prolonged ex-
pression of the repeat or additional genetic or environmen-
tal factors might be needed to drive TDP-43 dysfunction.
Importantly, TDP-43 function could also be affected with-
out the presence of TDP-43 positive aggregates [13]. The
absence of DPR pathology was assessed with a poly-GA
antibody [6]. We could not detect poly-GA aggregation in
brain tissue from bigenic mice, but only revealed GA-
positive inclusions in C9orf72 patient hippocampus controlmaterial illustrating lack of DPR pathology in this mouse
model (Figure 2). The mice did not develop any obvious
behavioral phenotype and showed no cell loss. The neuro-
toxic effect of the C9orf72 hexarepeat expansion has been
suggested by both RNA- and protein-mediated pathology
[7]. Due to lack of DPR pathology, this mouse is a good
model to investigate whether toxicity can be driven by the
repeat RNA only. Future studies focusing on molecular
changes and behavior deficits in our mouse model can
provide additional insight in disease progression, revers-
ibility and create options for therapeutic intervention. In
conclusion, we demonstrate that solely expression of the
GGGGCC repeat outside the C9orf72 context results in
ubiquitin-positive inclusions, which is a pathological hall-
mark in postmortem brain from ALS and FTD patients.
Our data on this first C9orf72 mouse model argues in
favor for a gain-of-function pathological mechanism in
C9orf72 associated ALS and FTD.
All animal experiments were conducted with the
permission of the local animal welfare committee (DEC).
Experiments on human brain material were done under
informed consent and approved by the Medical Ethical
Test Committee (METC). Human paraffin embedded
brain material was provided by the Dutch brain bank
(Nederlandse Hersenbank NHB).
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Figure 2 Absence of DPR pathology in brain of 80GGGGCC RNA expressing mouse. A) GA positive inclusions in the hippocampus of
C9orf72FTD patient. B) the striatum of bigenic mice treated with dox for 12 weeks shows no GA positive inclusions.
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